pegylated interferon alfa
pegylated interferon alfa is a biological therapy with 8 clinical trials. Historical success rate of 83.3%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
5
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
83.3%
5 of 6 finished
16.7%
1 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D
Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
Interferon Alfa in Treating Patients With Advanced Kidney Cancer
Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma
Clinical Trials (8)
Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D
Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
Interferon Alfa in Treating Patients With Advanced Kidney Cancer
Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C
All 8 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 8